Cardiac Phenotypes, Genetics, and Risks in Familial Noncompaction Cardiomyopathy.


Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
09 04 2019
Historique:
received: 01 07 2018
revised: 10 12 2018
accepted: 17 12 2018
entrez: 6 4 2019
pubmed: 6 4 2019
medline: 25 2 2020
Statut: ppublish

Résumé

There is overlap in genetic causes and cardiac features in noncompaction cardiomyopathy (NCCM), hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). The goal of this study was to predict phenotype and outcome in relatives according to the clinical features and genotype of NCCM index cases. Retrospective DNA and cardiac screening of relatives of 113 families from 143 index patients were used to classify NCCM cases according to the cardiac phenotype. These cases were classified as isolated NCCM, NCCM with left ventricular (LV) dilation (DCM), and NCCM with LV hypertrophy (HCM). In 58 (51%) families, screening identified 73 relatives with NCCM and 34 with DCM or HCM without NCCM. The yield of family screening was higher in families with a mutation (p < 0.001). Fifty-four families had a mutation. Nonpenetrance was observed in 37% of the relatives with a mutation. Index cases were more often symptomatic than affected relatives (p < 0.001). NCCM with DCM (53%) was associated with LV systolic dysfunction (p < 0.001), increased risk for major adverse cardiac events, mutations in the tail of MYH7 (p < 0.001), and DCM without NCCM in relatives (p < 0.001). Isolated NCCM (43%) was associated with a milder course, mutations in the head of MYH7, asymptomatic NCCM (42%) (p = 0.018), and isolated NCCM in relatives (p = 0.004). NCCM with HCM (4%) was associated with MYBPC3 and HCM without NCCM in relatives (p < 0.001). The phenotype of relatives may be predicted according to the NCCM phenotype and the mutation of index patients. NCCM phenotypes were related to outcome. In this way, clinical and genetic features of index patients may help prediction of outcome in relatives.

Sections du résumé

BACKGROUND
There is overlap in genetic causes and cardiac features in noncompaction cardiomyopathy (NCCM), hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM).
OBJECTIVES
The goal of this study was to predict phenotype and outcome in relatives according to the clinical features and genotype of NCCM index cases.
METHODS
Retrospective DNA and cardiac screening of relatives of 113 families from 143 index patients were used to classify NCCM cases according to the cardiac phenotype. These cases were classified as isolated NCCM, NCCM with left ventricular (LV) dilation (DCM), and NCCM with LV hypertrophy (HCM).
RESULTS
In 58 (51%) families, screening identified 73 relatives with NCCM and 34 with DCM or HCM without NCCM. The yield of family screening was higher in families with a mutation (p < 0.001). Fifty-four families had a mutation. Nonpenetrance was observed in 37% of the relatives with a mutation. Index cases were more often symptomatic than affected relatives (p < 0.001). NCCM with DCM (53%) was associated with LV systolic dysfunction (p < 0.001), increased risk for major adverse cardiac events, mutations in the tail of MYH7 (p < 0.001), and DCM without NCCM in relatives (p < 0.001). Isolated NCCM (43%) was associated with a milder course, mutations in the head of MYH7, asymptomatic NCCM (42%) (p = 0.018), and isolated NCCM in relatives (p = 0.004). NCCM with HCM (4%) was associated with MYBPC3 and HCM without NCCM in relatives (p < 0.001).
CONCLUSIONS
The phenotype of relatives may be predicted according to the NCCM phenotype and the mutation of index patients. NCCM phenotypes were related to outcome. In this way, clinical and genetic features of index patients may help prediction of outcome in relatives.

Identifiants

pubmed: 30947911
pii: S0735-1097(19)30497-8
doi: 10.1016/j.jacc.2018.12.085
pii:
doi:

Substances chimiques

Carrier Proteins 0
Connectin 0
MYH7 protein, human 0
TTN protein, human 0
myosin-binding protein C 0
Cardiac Myosins EC 3.6.1.-
Myosin Heavy Chains EC 3.6.4.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1601-1611

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Jaap I van Waning (JI)

Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, the Netherlands.

Kadir Caliskan (K)

Department of Cardiology, Erasmus Medical Center, Rotterdam, the Netherlands.

Michelle Michels (M)

Department of Cardiology, Erasmus Medical Center, Rotterdam, the Netherlands.

Arend F L Schinkel (AFL)

Department of Cardiology, Erasmus Medical Center, Rotterdam, the Netherlands.

Alexander Hirsch (A)

Department of Cardiology, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Radiology, Erasmus Medical Center, Rotterdam, the Netherlands.

Michiel Dalinghaus (M)

Department of Pediatrics, Erasmus Medical Center, Rotterdam, the Netherlands.

Yvonne M Hoedemaekers (YM)

Department of Clinical Genetics, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Marja W Wessels (MW)

Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, the Netherlands.

Arne S IJpma (AS)

Department of Pathology, Erasmus Medical Center, Rotterdam, the Netherlands.

Robert M W Hofstra (RMW)

Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, the Netherlands.

Marjon A van Slegtenhorst (MA)

Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, the Netherlands.

Danielle Majoor-Krakauer (D)

Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, the Netherlands. Electronic address: d.majoor-krakauer@erasmusmc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH